Key facts
- Notable investors include Fifty Years.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Birdwood
- ·The full record, as it builds
Funding rounds
No funding rounds for Birdwood are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Birdwood
Operator of a drug discovery platform designed for identifying novel therapeutic mechanisms through induced proximity. The company integrates adaptive AI-driven compound screening, proprietary molecular targeting strategies, to uncover previously inaccessible biological interactions, enabling pharmaceutical researchers and biotechnology companies to accelerate the development of precision medicines, expand the scope of druggable targets, and improve transnational outcomes across early-stage therapeutic programs.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2024
- Website
- birdwoodtherapeutics.com/
- Ownership
- Privately Held (backing)
Birdwood doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Birdwood shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Birdwood in its N-PORT filings yet. We sweep new filings monthly.